Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G G Chabot

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patientsM de Forni, G G Chabot, J P Armand, et al.
Cancer Research|September 1, 1988
Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopyJ L Evelhoch, M C Bissery, G G Chabot, et al.
Carcinogenesis|July 1, 1993
Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinomaF Janot, L Massaad, V Ribrag, et al.
Head & Neck|March 1, 1994
Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissuesO Parise, F Janot, B Luboinski, et al.
Cancer|June 1, 1990
A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanomaL E Flaherty, B G Redman, G G Chabot, et al.
Anti-Cancer Drugs|February 1, 1996
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patientsD Abigerges, J P Armand, G G Chabot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Cancer Research|August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patientsM de Forni, R Bugat, G G Chabot, et al.
Cancer Research|April 1, 1993
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor modelJ N Munck, M Riggi, P Rougier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastasesJ N Munck, P Rougier, G G Chabot, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patientsM de Forni, G G Chabot, J P Armand, et al.
Cancer Research|September 1, 1988
Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopyJ L Evelhoch, M C Bissery, G G Chabot, et al.
Carcinogenesis|July 1, 1993
Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinomaF Janot, L Massaad, V Ribrag, et al.
Head & Neck|March 1, 1994
Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissuesO Parise, F Janot, B Luboinski, et al.
Cancer|June 1, 1990
A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanomaL E Flaherty, B G Redman, G G Chabot, et al.
Anti-Cancer Drugs|February 1, 1996
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patientsD Abigerges, J P Armand, G G Chabot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Cancer Research|August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patientsM de Forni, R Bugat, G G Chabot, et al.
Cancer Research|April 1, 1993
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor modelJ N Munck, M Riggi, P Rougier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastasesJ N Munck, P Rougier, G G Chabot, et al.
Pageof 6